Top Markets
Coin of the day
Elicio Therapeutics, Inc. Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.

ELTX
Rank in Stocks #24617
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Share Price
$3.09
Market Cap
$58.82M
Change (1 day)
0.33%
Change (1 year)
-73.01%
Country
US
Trade Elicio Therapeutics, Inc. (ELTX)

Category

Stock price history for Elicio Therapeutics, Inc. (ELTX)
Highest end of day price: $3.10 on 2026-08-01

Lowest end of day price: $5.88 on 2023-11-01
Stock price history of Elicio Therapeutics, Inc. from 2023 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) 9.17%
2025 59.27%
2024 -21.55%
2023 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$550.92 38.61%
US
$1.06K 59.05%
NL
$147.61 462.97%
US
$118.70 -18.24%
AU
$770.19 9.84%
CH